Leerink Partners Raises the PT Vericel (VCEL), Maintains a Buy Rating

Vericel Corporation (NASDAQ:VCEL) is one of the Best Small-Cap Growth Stocks to Buy Right Now. On August 4, Mike Kratky from Leerink Partners raised the firm’s price target on Vericel Corporation (NASDAQ:VCEL) from $50 to $57, while maintaining a Buy rating on the stock.

The analyst noted that the company missed revenue estimates for the fiscal second quarter slightly. However, management’s outlook and strategic plan suggest better results during the second half of the year. Kratky noted that the conversion rates for MACI Arthro, which refer to the percentage of patients who move from an initial biopsy to receiving a MACI implant using the less invasive arthroscopic technique, are aligning with the traditional methods. This indicates  that the ongoing training and activations could drive growth in biopsies and implants through 2026.

Leerink Partners Raises the PT Vericel (VCEL), Maintains a Buy Rating

A lab worker holding a vial of biopharmaceuticals for cellular therapies.

Moreover, the analyst also finds that the current valuation of Vericel Corporation (NASDAQ:VCEL) is below its historic average and noted that management expects stable expenses for the rest of the year. Kratky finds the company’s risk/reward situation attractive.

Vericel Corporation (NASDAQ:VCEL) is a biopharmaceutical company that develops advanced therapies for sports medicine and severe burn care.

While we acknowledge the potential of VCEL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than VCEL and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.